PMID- 28570035
OWN - NLM
STAT- MEDLINE
DCOM- 20181029
LR  - 20220129
IS  - 1742-4658 (Electronic)
IS  - 1742-464X (Print)
IS  - 1742-464X (Linking)
VI  - 285
IP  - 1
DP  - 2018 Jan
TI  - Metabolic rewiring in mutant Kras lung cancer.
PG  - 28-41
LID - 10.1111/febs.14125 [doi]
AB  - Lung cancer is the leading cause of cancer-related death worldwide, reflecting an 
      unfortunate combination of very high prevalence and low survival rates, as most 
      cases are diagnosed at advanced stages when treatment efficacy is limited. Lung 
      cancer comprises several disease groups with non small cell lung cancer (NSCLC) 
      accounting for ~ 85% of cases and lung adenocarcinoma being its most frequent 
      histological subtype. Mutations in Kirsten rat sarcoma viral oncogene homologue 
      (KRAS) affect ~ 30% of lung adenocarcinomas but unlike other commonly altered 
      proteins (EGFR and ALK, affected in ~ 14% and 7% of cases respectively), mutant 
      KRAS remains untargetable. Therapeutic strategies that rely instead on the 
      inhibition of mutant KRAS functional output or the targeting of mutant KRAS 
      cellular dependencies (i.e. synthetic lethality) are an appealing alternative 
      approach. Recent studies focused on the metabolic properties of mutant KRAS lung 
      tumours have uncovered unique metabolic features that can potentially be 
      exploited therapeutically. We review these findings here with a particular focus 
      on in vivo, physiologic, mutant KRAS activity.
CI  - (c) 2017 Federation of European Biochemical Societies.
FAU - Kerr, Emma M
AU  - Kerr EM
AD  - MRC Cancer Unit, University of Cambridge, UK.
FAU - Martins, Carla P
AU  - Martins CP
AD  - MRC Cancer Unit, University of Cambridge, UK.
LA  - eng
GR  - MC_UU_12022/4/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170622
PL  - England
TA  - FEBS J
JT  - The FEBS journal
JID - 101229646
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (KRAS protein, human)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adenocarcinoma/*genetics/metabolism/therapy
MH  - Animals
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/metabolism/therapy
MH  - Glucose/metabolism
MH  - Humans
MH  - Lung Neoplasms/*genetics/metabolism/therapy
MH  - *Mutation
MH  - Proto-Oncogene Proteins p21(ras)/*genetics/metabolism
PMC - PMC6005344
MID - EMS77854
OTO - NOTNLM
OT  - lung cancer
OT  - metabolism
OT  - mouse models
OT  - mutant Kras
OT  - therapy
EDAT- 2017/06/02 06:00
MHDA- 2018/10/30 06:00
PMCR- 2019/01/01
CRDT- 2017/06/02 06:00
PHST- 2017/01/27 00:00 [received]
PHST- 2017/04/13 00:00 [revised]
PHST- 2017/05/30 00:00 [accepted]
PHST- 2017/06/02 06:00 [pubmed]
PHST- 2018/10/30 06:00 [medline]
PHST- 2017/06/02 06:00 [entrez]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 10.1111/febs.14125 [doi]
PST - ppublish
SO  - FEBS J. 2018 Jan;285(1):28-41. doi: 10.1111/febs.14125. Epub 2017 Jun 22.